Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
Intern Med. 2022;61(14):2215-2219. doi: 10.2169/internalmedicine.9513-22. Epub 2022 Jul 15.ABSTRACTA 52-year-old man with mantle cell lymphoma treated with bendamustine and rituximab developed prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite elevated titers of anti-spike IgG antibody, protracted pancytopenia persisted for more than six months. Finally, the anti-SARS CoV-2 vaccine, BNT162b2, was administered, which improved his blood cell count and eliminated the virus. The increased anti-spike IgG titer and lymphocyte count after vaccination suggested that both humoral and cellular immunity acted in coordination to eliminate the virus.PMID:35850990 | DOI:10.2169/internalmedicine.9513-22
Source: Internal Medicine - Category: Internal Medicine Authors: Masao Hagihara Yui Imai Tomoyuki Uchida Shin Ohara Morihiro Inoue Tomiyuki Sugi Keiko Mitamura Source Type: research
More News: Coronavirus | Covid Vaccine | COVID-19 | Internal Medicine | Lymphoma | Pancytopenia | Respiratory Medicine | Rituxan | SARS | Treanda | Vaccines